Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.

Autor:	González-Muñoza C; H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain).; Departament de Medicina, Universitat Autònoma de Barcelona (Barcelona, Spain)., Calafat M; H. Universitari Germans Trias i Pujol (Gastroenterology Department, Badalona, Spain) and CIBEREHD (Madrid, Spain)., Gisbert JP; H. de La Princesa (Gastroenterology Department, Madrid) and Instituto de Investigación Sanitaria Princesa (IIS-IP, Madrid, Spain), Universidad Autónoma de Madrid (UAM, Madrid, Spain) and CIBEREHD (Madrid, Spain)., Iglesias E; H. Universitario Reina Sofía (Gastroenterology Department, Córdoba, Spain)., Mínguez M; H.Clínico Valencia (Gastroenterology Department, Valencia, Spain)., Sicilia B; H. Universitario de Burgos (Gastroenterology Department, Burgos, Spain)., Aceituno M; H. Universitari Mútua Terrassa (Gastroenterology Department, Terrassa, Spain) and CIBEREHD (Madrid, Spain)., Gomollón F; H.Clínico Universitario Lozano Blesa (Gastroenterology Department, Zaragoza, Spain) and CIBEREHD (Madrid, Spain)., Calvet X; H. Parc Taulí (Gastroenterology Department, Sabadell, Spain) and CIBEREHD (Madrid, Spain)., Ricart E; H. Clínic Barcelona (Gastroenterology Department, Barcelona) and CIBEREHD (Madrid, Spain) and IDIBAPS (Barcelona, Spain)., De Castro L; H. Alvaro Cunqueiro (Gastroenterology Department, Vigo, Spain)., Rivero M; H. Marqués Valdecilla (Gastroenterology Department, Santander, Spain) and IDIVAL (Santander, Spain)., Mesonero F; H. Universitario Ramón y Cajal (Gastroenterology Department, Madrid, Spain)., Márquez L; H. del Mar (Gastroenterology Department, Barcelona, Spain) and IMIM (Barcelona, Spain)., Nos P; H. Universitario y Politécnico La Fe (Gastroenterology Department, Valencia, Spain)., Rodríguez-Pescador A; H. Universitario Galdakao (Gastroenterology Department, Bilbao, Spain)., Guardiola J; H. Universitario de Bellvitge (Gastroenterology Department, L'Hospitalet del Llobregat, Spain)., García-Sepulcre M; H. General Universitario de Elche (Gastroenterology Department, Elche, Spain)., García-López S; H. Universitario Miguel Servet (Gastroenterology Department, Zaragoza, Spain)., Lorente-Poyatos RH; H. General Universitario Ciudad Real (Gastroenterology Department, Ciudad Real, Spain)., Alba C; H. Clínico San Carlos (Gastroenterology Department, Madrid, Spain)., Sánchez-Ocaña R; H. Río Hortega (Gastroenterology Department, Valladolid, Spain)., Vera I; H. Universitario Puerta Hierro Majadahonda (Gastroenterology Department, Madrid, Spain)., Madero L; H.General Universitario Dr. Balmis de Alicante (Gastroenterology Department, Alicante, Spain)., Riestra S; H. U. Central de Asturias (Gastroenterology Department, Oviedo, Spain) and ISPA (Oviedo, Spain)., Navarro-Llavat M; H. Moisès Broggi (Gastroenterology Department, Sant Joan Despí, Spain)., Pérez-Calle JL; H. U. Fundación Alcorcón (Gastroenterology Department, Alcorcón, Spain)., Camps B; H. General Granollers (Gastroenterology Department, Granollers, Spain)., Van Domselaar M; H. U. de Torrejón (Gastroenterology Department, Torrejón de Ardoz, Spain)., Lucendo AJ; H. Público General Tomelloso (Gastroenterology Department, Tomelloso, Spain)., Martín-Arranz MD; H. U. La Paz (Gastroenterology Department, Madrid, Spain)., Montoro-Huguet MA; H. General San Jorge (Gastroenterology Department, Huesca, Spain)., Sierra-Ausín M; Complejo Asistencial Universitario León (Gastroenterology Department, León, Spain)., Llaó J; Althaia Xarxa Assistencial Universitària de Manresa (Gastroenterology Department, Manresa, Spain)., Carpio D; Complexo Hospitalario de Pontevedra (Gastroenterology Department, Pontevedra, Spain)., Varela P; H. U. Cabueñes (Gastroenterology Department, Gijón, Spain)., Merino O; H. U. Cruces (Gastroenterology Department, Baracaldo, Spain)., Fernández-Salazar LI; H. Clínico Universitario Valladolid (Gastroenterology Department, Valladolid, Spain)., Piqueras M; Consorci Sanitari Terrassa (Gastroenterology Department, Terrassa, Spain)., Sesé E; H. U. Arnau Vilanova (Gastroenterology Department, Lleida, Spain)., Busquets D; H. U. de Girona Doctor Josep Trueta (Gastroenterology Department, Girona, Spain)., Tardillo C; H. U. Nuestra Señora de Candelaria (Gastroenterology Department, Sta. Cruz de Tenerife, Spain)., Maroto N; H. de Manises (Gastroenterology Department, Manises, Spain)., Riera J; H. U. Son Llàtzer (Gastroenterology Department, Palma de Mallorca, Spain)., Martínez-Flores C; Complejo Hospitalario la Mancha Centro (Gastroenterology Department, Alcázar de San Juan, Spain)., Muñoz F; H. U. Salamanca (Gastroenterology Department, Salamanca, Spain)., Gordillo-Ábalos J; H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain)., Bertoletti F; H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain)., Garcia-Planella E; H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain)., Domènech E; Departament de Medicina, Universitat Autònoma de Barcelona (Barcelona, Spain).; H. Universitari Germans Trias i Pujol (Gastroenterology Department, Badalona, Spain) and CIBEREHD (Madrid, Spain).
Jazyk:	angličtina
Zdroj:	Postgraduate medical journal [Postgrad Med J] 2024 Oct 18; Vol. 100 (1189), pp. 836-844.
DOI:	10.1093/postmj/qgae076
Abstrakt:	Background and Aims: Familial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of a familial history of IBD on the use of medical and surgical treatments in the biological era. Methods: Patients included in the prospectively maintained ENEIDA database and diagnosed with IBD after 2005 were included. Familial forms were defined as those cases with at least one first-degree relative diagnosed with IBD. Disease phenotype, the use of biological agents, or surgical treatments were the main outcomes. Results: A total of 5263 patients [2627 Crohn's disease (CD); 2636 ulcerative colitis (UC)] were included, with a median follow-up of 31 months. Of these, 507 (10%) corresponded to familial forms. No clinical differences were observed between familial and sporadic IBD forms except a lower age at IBD diagnosis and a higher rate of males in familial forms of UC. In CD, the proportions of patients treated with thiopurines (54.4% vs 46.7%; P = .015) and survival time free of thiopurines (P = .009) were lower in familial forms. No differences were found regarding the use of biological agents. Concerning surgery, a higher rate of intestinal resections was observed in sporadic CD (14.8% vs 9.9%, P = .027). No differences were observed in UC. Conclusions: In the era of biological therapies, familial and sporadic forms of IBD show similar phenotypes and are managed medically in a similar way; whether these is due to lack of phenotypical differences or an effect of biological therapies is uncertain. What is already known on this topic: IBD's etiopathogenesis points to an interaction between environmental and genetic factors, being familial history a controversial prognostic factor. Biological agents use and need for surgery regarding familial or sporadic forms of IBDs present conflicting results. What this study adds: Familial and sporadic forms of IBD have similar phenotypes and are managed medically and surgically in a similar way. How this study might affect research, practice or policy: Familial aggregation should not be considered a factor associated with more aggressive disease. (© The Author(s) 2024. Published by Oxford University Press on behalf of Fellowship of Postgraduate Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu